Pfeifer Retiring as AC Immune CEO — and More Biotech C-Suite Moves

Why It Matters

Pfeifer’s exit marks a generational leadership change at a key neuro‑degeneration player, while Mendonça’s hire underscores Cellular Intelligence’s ambition to fast‑track a high‑profile Parkinson’s therapy to market.

Key Takeaways

• Andrea Pfeifer retires after 23 years leading AC Immune
• Martin Zügel serves as interim CEO during successor search
• Nuno Mendonça joins Cellular Intelligence as new CMO
• Cellular Intelligence acquires Novo Nordisk Parkinson’s cell‑therapy platform

Pulse Analysis

Andrea Pfeifer’s retirement closes a chapter for AC Immune, a company that has become a cornerstone of Swiss neuro‑degeneration research. Under her stewardship, the firm secured multiple partnerships, advanced its amyloid‑targeting pipeline, and listed on NASDAQ. Her transition to an honorary board role preserves strategic continuity, but the interim appointment of Martin Zügel signals a period of evaluation as the board seeks a permanent CEO who can balance scientific rigor with commercial scaling.

The biotech sector is witnessing a wave of C‑suite reshuffles, reflecting heightened investor scrutiny and the need for leaders who can navigate complex regulatory pathways. AC Immune’s leadership change is emblematic of this trend; a fresh CEO could recalibrate the company’s focus toward late‑stage trials and potential licensing deals, crucial for sustaining valuation in a crowded neurology market. Stakeholders will watch closely for signals about pipeline prioritization, especially as competitors vie for dominance in Alzheimer’s and Parkinson’s therapeutics.

Cellular Intelligence’s acquisition of a Parkinson’s disease cell‑therapy from Novo Nordisk, coupled with Nuno Mendonça’s appointment as CMO, positions the Boston firm to accelerate clinical translation. Mendonça brings deep experience in neuro‑immunology and regulatory affairs, which should streamline the move from model‑building to first‑in‑human studies. The deal not only expands Cellular Intelligence’s asset base but also illustrates how larger pharma entities like Novo Nordisk are divesting early‑stage programs to more agile partners, creating opportunities for rapid innovation in neuro‑degenerative disease treatment.